an oral Janus kinase inhibitor for the treatment of RA. Live zoster vaccine (LZV) has shown 70% efficacy in immunocompetent adults aged 50-59 years and 51% efficacy in those aged ≥60 years. 2 We previously reported that pts with RA on background methotrexate who started 3 months of treatment with tofacitinib after LZV had similar varicella zoster virus (VZV)-specific immunity to placebo (PBO) pts, and their VZV immunity at Week 6 post-vaccination was comparable with healthy individuals aged ≥50 years.
LB0003 TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS ADALIMUMAB WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM ORAL STRATEGY, A PHASE 3B/4 RANDOMISED TRIAL
15-25 mg/wk. The primary endpoint was ACR50 at Month (Mo) 6. Non-inferiority between treatments was declared if the lower bound of 98.34% two-sided confidence intervals of the difference of ACR50 response at Mo 6 was larger than -13% (based on meta analysis of ADA trials 1 ), and superiority if it was larger than 0%. Other endpoints included: ACR20/50/70 and least-squares mean changes from BL in SDAI, DAS28-4(ESR) and HAQ-DI at Mos 6 and 12. Safety was assessed throughout the trial. Results: 1146 pts were randomised and treated (5 mg mono BID: n=384; 5 mg BID+MTX: n=376; ADA+MTX: n=386). Demographics and BL disease characteristics were similar across groups. Most pts were female (82.7-83.1%), white (75.9-77.1%), with a mean age of 49.7-50.7 years, median disease duration of 5.4-6.1 years and mean HAQ-DI score of 1.6. Across groups, 80.2-81.6% of pts completed the study. ACR50 response rate at Mo 6 was 38.3% for 5 mg mono BID, 46.0% for 5 mg BID+MTX and 43.8% for ADA+MTX. Non-inferiority was demonstrated for 5 mg BID+MTX vs ADA+MTX (P<0.0001) but not for 5 mg mono BID vs ADA+MTX (P=0.0512) or 5 mg mono BID vs 5 mg BID+MTX (P=0.2101) which, although numerically different, were not statistically different ( Figure) . Tofacitinib monotherapy achieved the efficacy expected of an effective immunomodulator in this pt population. Secondary efficacy analyses were generally consistent with the primary analysis (Table) . Adverse event (AE), serious AE and discontinuation due to AE rates were generally clinically similar across groups, though numerically fewer pts had increased alanine aminotransferase with 5 mg mono BID vs 5 mg BID+MTX or ADA+MTX. Background: Triple therapy (anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins) is empirically prescribed for the management of catastrophic antiphospholipid syndrome (CAPS). However, previous analyses have been inconsistent regarding the beneficial effect of triple therapy on patients' survival. Objectives: The objective of this study was to assess the effect that triple therapy has on the mortality risk of CAPS patients. Methods: In a cohort including 525 episodes of CAPS (CAPS Registry), we evaluated the relationship between triple therapy and mortality. Patients were grouped in three based on their treatments: a) triple therapy (anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins); b) drugs included in the triple therapy but in different combinations; c) none of Abstract OP0232 - Table 1 0-1y 1-2y 2-3y 3-4y 4-5y 5-6y 6-7y 7-8y 8-9y 9-10y 10-11y 
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